Catalog No.
Product Name
Application
Product Information
Citations
-
NMDA receptor ion channel antagonist
ARL-15896 is a novel N-methyl-D-aspartate receptor ion channel antagonist.- Robert A. Volkmann, .et al. , PLoS One, 2016, 11(2): e0148129 PMID: 26829109
-
NMDA receptor antagonist
Memantine hydrochloride is an antagonist at the NMDA receptor, binding to the ion channel site. it was used in the treatment of Parkinsonism.- Xuefeng Hu, .et al. , Research Square, 2024, Apr 12
-
non-NMDA receptor antagonist
DNQX Disodium is a water-soluble form of selective non-NMDA receptor antagonist DNQX. -
NMDA Receptor Antagonist
(Rac)-PEAQX is an NMDA receptor antagonist that effectively modulates synaptic transmission by inhibiting NMDA receptor activity. It has demonstrated the ability to activate caspase-3, inducing apoptotic pathways in cortical striatal slice cultures. This compound is valuable for research applications focusing on neurodegenerative diseases, synaptic plasticity, and mechanisms of neuronal apoptosis. -
Pregnanolone, also known as eltanolone, is an endogenous inhibitory neurosteroid that is produced in the body from progesterone.
-
NMDA Antagonist
Ensaculin free base is a potent NMDA antagonist that exhibits high affinities for serotonergic 5-HT1A and 5-HT7 receptors, as well as adrenergic α1 and dopaminergic D2 and D3 receptors. This compound has demonstrated memory-enhancing properties and shows potential as an antidementia agent, influencing multiple neurotransmitter systems. Its diverse receptor activity makes it a valuable tool for researching cognitive function and neurodegenerative disorders. -
CRMP2-NMDAR Inhibitor
TAT-CBD3 is a 15-amino acid peptide derived from CRMP2 that incorporates the TAT cell-penetrating motif from HIV-1, enabling efficient cellular uptake. This peptide disrupts the interaction between CRMP2 and NMDA receptors (NMDAR) while maintaining NMDAR localization. TAT-CBD3 is valuable for research applications focused on neurobiology and synaptic signaling, particularly in studies investigating the role of CRMP2 in neuronal function and related disorders. -
NMDA Agonist
Cis-ACPD is a potent agonist of the NMDA receptor, exhibiting an IC50 of 3.3 µM. Additionally, it selectively activates group II metabotropic glutamate receptors, with EC50 values of 13 µM for mGluR2 and 50 µM for mGluR4. The compound is widely used in neuropharmacological research to study excitatory neurotransmission and the role of glutamate receptors in various neurological disorders. -
NMDA Receptor Modulator
Neboglamine hydrochloride is a positive modulator of the glycine site on the NMDA receptor, facilitating increased receptor activity. This compound has demonstrated potential in addressing aspects of schizophrenia and related neurological disorders. Researchers can utilize Neboglamine hydrochloride to explore its effects on synaptic transmission and neuroplasticity, contributing to a deeper understanding of NMDA receptor dynamics in psychiatric conditions. -
NMDA Receptor Antagonist
Gavestinel sodium salt is a selective, non-competitive antagonist of the NMDA receptor, targeting the glycine site with a pKi of 8.5. This compound exhibits potent activity in modulating NMDA receptor function, making it valuable for research applications related to neuroprotection and acute ischemic stroke. Its oral bioavailability enhances its potential as a tool for studying NMDA receptor-mediated pathways in various neurological conditions. -
NMDA Receptor Antagonist
Gavestinel (GV 150526) is a selective and potent antagonist of the glycine site on the NMDA receptor. It exhibits neuroprotective effects, making it a valuable tool for research into neurodegenerative diseases and neurological disorders. Its ability to modulate excitotoxicity highlights its potential in studying synaptic transmission and neuronal survival. -
NMDA Receptor Antagonist
DL-AP5 sodium is a competitive antagonist of the NMDA (N-methyl-D-aspartate) receptor. It exhibits notable antinociceptive activity, making it valuable for pain research. Additionally, DL-AP5 sodium effectively blocks ion channels in the rabbit retina, providing insights into retinal pharmacology and neurological studies. -
NMDA Receptor Antagonist
Remacemide is a non-competitive antagonist of the NMDA receptor, demonstrating low-affinity binding. It exhibits neuroprotective properties in preclinical models of hypoxia and ischemic stroke, making it a valuable tool in neurological research. Furthermore, Remacemide possesses anticonvulsant activity and is relevant in the study of neurodegenerative disorders such as Parkinson's disease and Huntington's disease. -
NMDA Receptor NR2B Antagonist
EMD-95885 is a selective antagonist of the NR2B subunit of NMDA receptors, exhibiting an IC50 of 3.9 nM. This specificity enables EMD-95885 to effectively block NR2B-containing NMDA receptor activity without engaging other binding sites on the receptor. It is valuable for research focusing on neurobiology, synaptic plasticity, and the mechanisms underlying neurological disorders. -
NMDA Antagonist
(RS)-CPP ((±)-CPP) is a potent and selective antagonist of the N-methyl-D-aspartate (NMDA) receptor. By inhibiting NMDA receptor-mediated central neuron responses, (RS)-CPP demonstrates anticonvulsant properties. This compound is primarily utilized in neurological research to explore mechanisms of neuroprotection, excitotoxicity, and seizure disorders. -
NMDA Receptor Inhibitor
(R)-CPP is a potent antagonist of the NMDA receptor, effectively inhibiting its activity. It is utilized in various research applications related to neuropharmacology and the study of excitatory neurotransmission. This compound is important for exploring the role of NMDA receptors in neurological disorders and for evaluating potential therapeutic interventions. -
NMDAR Modulator
NYX-2925 is an orally active NMDAR modulator that specifically restores activated Src and its phosphorylation sites on GluN2A and GluN2B in the medial prefrontal cortex. This compound does not affect CAMKII and is devoid of addictive, sedative, or ataxic side effects. NYX-2925 is a valuable tool for investigating NMDA receptor-related central nervous system disorders. -
NMDAR Antagonist
Blixeprodil is a selective antagonist of the N-methyl-D-aspartate receptor (NMDAR) with a binding affinity (Ki) of 3.25 µM in rat cortical tissue. It effectively inhibits NR1/2A-NMDAR-mediated currents in HEK293 cells, exhibiting an IC50 value of 1.192 µM. Preclinical studies demonstrate its antidepressant properties in animal models, and Blixeprodil's ability to cross the blood-brain barrier makes it a valuable tool for investigating neuropharmacological mechanisms and potential therapeutic applications in mood disorders. -
NMDAR Antagonist
(Rac)-Lanicemine is a potent NMDA receptor antagonist that functions as a low-trapping blocker of NMDA channels, exhibiting a Ki value between 0.56-2.1 μM. This compound demonstrates antidepressant properties, supported by IC50 values of 4-7 μM in CHO cells and 6.4 μM in Xenopus oocyte cells. Its unique pharmacological profile makes (Rac)-Lanicemine valuable for research investigating the mechanisms of depression and the role of NMDA receptors in neuropsychiatric disorders. -
NMDA receptor antagonist
Aptiganel hydrochloride is a non-competitive antagonist of the NMDA receptor, exhibiting significant neuroprotective properties. Its ability to modulate glutamate signaling positions it as a valuable tool in research focused on neurodegenerative diseases and conditions associated with excitotoxicity. Aptiganel hydrochloride is particularly relevant for exploring therapeutic approaches for stroke, traumatic brain injury, and various neurodegenerative disorders. -
NMDA Receptor Antagonist
L-701252 is a potent antagonist of the glycine site on the NMDA receptor, exhibiting an IC50 of 420 nM. This compound has demonstrated neuroprotective effects in models of global cerebral ischemia, making it a valuable tool for research into neurodegenerative diseases and excitotoxicity. Its efficacy in modulating NMDA receptor activity positions L-701252 as a promising candidate for studies focused on synaptic transmission and neurological disorders. -
NMDA Receptor Agonist
N-Methyl-DL-aspartic acid is a glutamate analogue that functions as an NMDA receptor agonist. This compound is primarily utilized in research pertaining to neurological disorders, aiding in the study of synaptic transmission and excitotoxicity associated with various neurodegenerative conditions. Its ability to activate NMDA receptors makes it a valuable tool for investigating the physiological and pathological roles of glutamatergic signaling in the central nervous system. -
NMDA Antagonist
Nelonemdaz potassium is an NR2B-selective, uncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors. This compound exhibits significant neuroprotective properties by mitigating cell death induced by NMDA and free radicals. It serves as a valuable tool in research focused on neuroprotection, neurodegenerative diseases, and the mechanisms underlying excitotoxicity. Its dual action as a NMDA antagonist and free radical scavenger supports its potential applications in therapeutic development for conditions linked to oxidative stress and neuronal injury. -
NMDA antagonist
PPDA is a subtype-selective antagonist of the NMDA receptor, specifically targeting the NR2C and NR2D subunits. This compound is known to inhibit NMDA receptor-mediated signaling, making it valuable for research on synaptic plasticity, neuroprotection, and neurological disorders. Its selective binding profile allows for more tailored studies on the role of specific NMDA receptor subtypes in various biological processes. -
Anti-NMDAR Antibody
ART5803 is a humanized IgG1 monoclonal antibody that targets the N-terminal domain of the NMDAR GluN1 subunit. This compound effectively inhibits NMDAR internalization induced by pathogenic autoantibodies and restores both cell-surface expression and functional activity of NMDAR. ART5803 has demonstrated efficacy in reversing behavioral abnormalities and restoring NMDAR expression in marmoset models of disease, making it a valuable tool for research on anti-NMDAR encephalitis. -
NMDA Antagonist
Fluoroethylnormemantine hydrochloride is an NMDA receptor antagonist, derived from Memantine. This compound demonstrates significant anti-amnesic, neuroprotective, and antidepressant-like properties, along with the ability to attenuate fear responses. It is suitable for research applications involving neuropharmacology and may serve as a valuable positron emission tomography (PET) tracer in studying NMDA receptor dynamics and related pathways in the central nervous system. -
NMDA Receptor Antagonist
CGP 37849 is a potent competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. This compound exhibits anticonvulsant properties in rodent models, as well as demonstrating antidepressant and anxiolytic-like effects. It serves as a valuable tool in research focused on neurological disorders and the modulation of synaptic transmission. -
Glycine/NMDA Partial Agonist/Antagonist
(R)-(+)-HA-966 functions as a partial agonist/antagonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. This compound selectively inhibits the activation of the mesolimbic dopamine system induced by amphetamine, making it relevant for studying addiction and dopamine-related disorders. Its ability to traverse the blood-brain barrier suggests potential applications in addressing conditions such as neuropathic and acute pain. -
NMDA Receptor Antagonist
SDZ 220-040 is a competitive antagonist of the NMDA receptor, exhibiting a pKi of 8.5. This compound is primarily employed in research investigating neurological diseases, offering insights into the mechanisms underlying neurodegeneration and synaptic dysfunction. Its specific targeting of NMDA receptors makes it a valuable reagent for pharmacological studies and the development of novel therapeutic strategies. -
NMDA Receptor Antagonist
Arcaine sulfate is a potent NMDA receptor antagonist that selectively inhibits glutamate signaling at this critical synaptic target. Its ability to modulate excitatory neurotransmission makes Arcaine sulfate a valuable tool for studying neurophysiological processes and evaluating the role of NMDA receptors in various neurological disorders. This compound is widely utilized in research exploring synaptic plasticity, neuroprotection, and the mechanisms underlying excitotoxicity. -
NMDA Agonist
(RS)-(Tetrazol-5-yl)glycine is a potent and selective agonist of the N-methyl-D-aspartate (NMDA) receptor. It exhibits effective stimulation with EC50 values of 99 nM and 1.7 μM for the GluN1/GluN2D and GluN1/GluN2A subtypes, respectively. This compound is utilized in research involving seizure activity and neuronal activation, as evidenced by its ability to induce Fos expression in mice models. -
NMDARs Negative Allosteric Modulator
UBP608 is a potent negative allosteric modulator of N-Methyl-D-aspartate receptors (NMDARs). This compound has demonstrated significant biological activity in modulating NMDAR function, making it a valuable tool for investigating neurological disorders. Its mechanism of action offers insights into synaptic transmission and neuroplasticity, facilitating research into therapeutic strategies for various cognitive and behavioral conditions. -
NMDA Receptor Modulator
Neboglamine is an N-methyl-D-aspartate (NMDA) receptor modulator that enhances neuronal activity in key brain regions including the prefrontal cortex, nucleus accumbens, and lateral septal nucleus. This compound has been shown to increase the levels of fos-like immunoreactivity (FLI)-positive cells and effectively restores NMDA-mediated neurotransmitter release. Additionally, Neboglamine demonstrates the ability to inhibit hyperlocomotion induced by phencyclidine, highlighting its potential for research in neuropharmacology and neuropsychiatric disorders. -
GluN1/GluN2A NMDAR Antagonist
TCN 213 is a selective, surmountable antagonist of the GluN1/GluN2A subunits of the N-methyl-D-aspartate receptor (NMDAR), exhibiting IC50 values of 0.55, 3.5, and 40 μM in the presence of 75, 750, and 7500 nM glycine, respectively. This compound serves a critical role in studying the pharmacological modulation of NMDAR expression in developing cortical neurons, making it a valuable tool for research in neurodevelopment and synaptic plasticity. -
NMDA Antagonist
L-689560 is a potent antagonist of the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the GluN1 glycine binding site. This compound is utilized extensively in radiolabeled ligand binding studies and is essential for investigating the roles of NMDA receptors in both normal neurological functions and various neurological disorders. L-689560 aids in advancing our understanding of synaptic transmission and neurotoxicity linked to excitatory neurotransmission. -
NMDA Receptor Antagonist
(S)-(-)-HA 966 is a γ-Hydroxybutyrate-like compound that functions as a weak NMDA receptor antagonist. It exhibits muscle relaxant properties and has been shown to prevent increased mesocorticolimbic dopamine metabolism associated with behavioral responses to restraint stress and conditioned fear. This reagent can be utilized in studies investigating neuropharmacology and stress-related behavioral models. -
NMDA receptor antagonist
Neramexane hydrochloride is an NMDA receptor antagonist that exhibits neuroprotective properties. This compound is primarily utilized in research related to central nervous system disorders, including Alzheimer's disease, as well as investigations into drug and alcohol dependence and pain mechanisms. Its ability to modulate excitatory neurotransmission makes it a valuable tool for studying neurodegenerative processes and addiction pathways. -
NMDAR Antagonist
NMDAR antagonist 3 is a selective antagonist of the N-methyl-D-aspartate (NMDA) receptor. This compound exhibits weak inhibitory activity against the NR1A/2B subtype, making it valuable for studies investigating the modulation of NMDA receptor signaling. Research applications include exploration of neurological conditions and behavioral studies involving synaptic plasticity and excitotoxicity. -
NMDA Receptor Modulator
PYD-106 is a selective positive allosteric modulator of GluN2C-containing NMDA receptors. This compound enhances the frequency and duration of single-channel currents induced by full agonists while displaying only modest modulation of glutamate and glycine efficacy. Notably, PYD-106 specifically boosts the activity of diheteromeric GluN1/GluN2C receptors without affecting triheteromeric GluN1/GluN2A/GluN2C receptors. Its unique mechanism holds promise for research focused on synaptic transmission and neuropharmacology. -
NR2B-Selective NMDA Antagonist
NMDA receptor antagonist 2 is a potent NR2B-selective NMDA receptor antagonist with an IC50 of 1.0 nM and a Ki of 0.88 nM. This compound is utilized to investigate the mechanisms underlying neuropathic pain and Parkinson's disease. Its selectivity for the NR2B subtype makes it a valuable tool for exploring potential therapeutic strategies in these neurological disorders. -
NMDA Antagonist
Midafotel is a potent and competitive NMDA antagonist, exhibiting an ED50 value of 39 nM. This compound induces pronounced stereotyped behaviors and demonstrates neuroprotective properties, making it valuable for studies focused on neurodegenerative diseases and synaptic plasticity. Its unique pharmacological profile positions Midafotel as a relevant tool for investigating NMDA receptor modulation in various research applications. -
NMDA NR2B Negative Allosteric Modulator
Satoprodil is a potent negative allosteric modulator of the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the NR2B subunit with an IC50 value of 123 nM. This compound exhibits significant biological activity in regulating glutamatergic neurotransmission and has potential research applications in neuropharmacology, particularly in the study of pain, mood disorders, and neurodegenerative diseases. -
NMDAR Agonist
TP-050 is a potent, orally active NMDAR agonist, selectively targeting the GluN2A and GluN2D subtypes with EC50 values of 0.51 μM and 9.6 μM, respectively. This compound effectively crosses the blood-brain barrier, facilitating its role in enhancing hippocampal long-term potentiation and promoting neuronal signal transmission. TP-050 offers valuable applications in neuroscience research, particularly in studies involving synaptic plasticity and cognitive function. -
NMDA NR2B Inhibitor
BZAD-01 is a selective inhibitor of the NMDA NR2B subunit, exhibiting a Ki value of 72 nM. This compound demonstrates significant biological activity by improving postural asymmetry and reducing Apomorphine-induced rotation. BZAD-01 is utilized in research applications focused on neurological disorders and synaptic transmission modulation. -
NMDA Receptor Antagonist
3-Methoxy PCE hydrochloride is an NMDA receptor antagonist, classified as an arylcyclohexylamine. With a pKi value of 7.22, it effectively inhibits NMDA receptor activity. This compound is primarily utilized in neuropharmacological studies and research focused on synaptic transmission and excitotoxicity pathways. -
NMDA Receptor Modulator
NMDA receptor modulator 2 is a potent modulator of the NMDA receptor, playing a critical role in glutamatergic neurotransmission. This compound exhibits significant neuroprotective properties and has potential applications in the study of neurological disorders, including Alzheimer's disease and other cognitive impairments. Its use in research can provide insights into synaptic plasticity and the mechanisms underlying neurodegeneration. -
NMDA Agonist
N-Phthaloylglutamic acid functions as a partial agonist of the NMDA receptor, specifically targeting the glutamate binding site with an affinity characterized by a Ki of 13 μM. Its biological activity contributes to the modulation of excitatory neurotransmission and may serve as a valuable tool in neuropharmacological research. This reagent is useful for studies investigating NMDA receptor dynamics and related neurological processes. -
NMDAR Blocker
NMDA receptor antagonist 4 is a uncompetitive, voltage-dependent antagonist of the N-methyl-D-aspartate receptor (NMDAR) with an IC50 of 1.93 μM. This orally active compound exhibits favorable blood-brain barrier permeability, making it suitable for in vivo studies. It is particularly relevant for research applications related to neurodegenerative diseases such as Alzheimer's disease.
